Increases in the number of persons with active epilepsy were indicated based on National Health Interview Survey data from 2010 to 2015, probably due to population growth.
The researchers observed significant increases in topiramate, rufinamide, and N-desmethylclobazam and a significant decrease in clobazam serum levels with increasing cannabidiol dose.
The researchers found that for individuals with partial seizures, levetiracetam performed statistically significantly better than carbamazepine and lamotrigine for time to withdrawal of allocated treatment.
Potiga, a potassium channel opener, was approved in 2011 as an adjunctive treatment for partial-onset seizures in patients with inadequate response to alternative treatments.
Study patients reported a 50% reduction in seizure severity as well as an improvement in mood among 49% of patients. Improvements in memory and achievement were seen in 38% and 39% of patient, respectively. Moreover, patients reported a 64% reduction in seizure worry.
The researchers found that the serum concentrations of carbamazepine, lamotrigine, levetiracetam, topiramate, and valproic acid decreased after the dietary therapies.
The data showed a reduction in the median frequency of convulsive seizure per month from 12.4 to 5.9 with cannabidiol vs. a reduction from 14.9 to 14.1 with placebo.
A 45-year-old man with a past history of IV drug use was found to be insufflating bupropion at his rehabilitation facility.
The sNDA submission includes data from five controlled clinical trials in adults with POS and three clinical studies demonstrating safety and tolerability in pediatric patients.
The C.O. Truxton product is packaged in 100- or 1000-count bottles in the following strengths: 15mg, 30mg, 60mg, and 100mg.
Proximagen announced promising data from the pivotal Phase 3 trial of USL261 (intranasal midazolam) for the rescue treatment of seizure clusters. The primary efficacy endpoint was treatment success, defined as achieving 1) termination of seizure(s) and 2) no recurrence of seizure(s)
The greatest risk factor for SUDEP was found to be generalized tonic-clonic seizures (GTCS), with a higher frequency of these types of seizures correlating to an increased risk of death.
The mislabeled drug could lead to a potential overdose for patients or their pet(s), resulting in severe intoxication, cardiogenic shock, renal failure, coma or death.
In August 2016, the FDA granted tentative approval of the Company's one of two supplemental New Drug Applications (sNDAs). The final approval was contingent on the pediatric exclusivity of the drug in the adolescent population that expired March 28, 2017.
Aptiom, a dibenzazepine carboxamide antiepileptic, is currently approved for use as monotherapy or adjunctive therapy for partial onset seizures (POS) in adults, the new supplemental NDA aims to extend this indication for the treatment of POS in children aged ≥4 years.
Male stroke patients are more than twice as likely as female patients to receive tissue plasminogen activator treatment within 30 minutes of hospital arrival, a new study has found.
A federal judge has ordered Regeneca Worldwide, a California dietary supplement distributor, to stop selling its products that were found to contain harmful ingredients including 1,3-dimethylamylamine (DMAA).
Concomitant use of valproic acid (VPA) and meropenem (MEPM) is associated with a decrease in VPA plasma levels, according to a study published online in the Journal of Clinical Pharmacy and Therapeutics.
In a study of female patients with epilepsy, retrospective data found that unintended pregnancy was common and varied by contraceptive type and antiepileptic drug (AED) stratification. Full findings are published in Neurology.